Cadrenal
CVKD
Cadrenal (CVKD) news
Recent news
Cadrenal Therapeutics - Phase 3 trial to assess bleeding as major safety endpoint using ISTH criteria
AInvest Wire · 8h agoCadrenal Therapeutics - FDA agrees to placebo control with standard anticoagulation in CAD-1005 phase 3 trial
AInvest Wire · 8h agoCadrenal Therapeutics - Co and FDA align on phase 3 study protocol for CAD-1005
AInvest Wire · 8h agoCadrenal Therapeutics announces positive outcome from FDA type D meeting for phase 3 registration study of cad-1005 in heparin-induced thrombocytopenia
AInvest Wire · 8h agoCadrenal Therapeutics - Quang X. Pham ceases to serve as interim CFO - SEC filing
Cadrenal Therapeutics Inc. (NASDAQ: CDTX) has announced that Quang X. Pham has ceased to serve as the company’s interim Chief Financial Officer, according to a recent SEC filing [1]. The filing indicates that Mr. Pham’s role as interim CFO ended on June 28, 2026. No further details regarding the…
AInvest Wire · Jun 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.